Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
77 JPY | 0.00% | -1.28% | -37.90% |
Apr. 15 | Modalis Therapeutics to See Reduced Expenses of 250 to 350 Million After Cutting Jobs | MT |
Feb. 23 | Modalis Therapeutics to Reduce Stated Capital and Capital Reserves | MT |
Sales 2022 | 40M 255K | Sales 2023 | - | Capitalization | 3.92B 25M |
---|---|---|---|---|---|
Net income 2022 | -2.7B -17.25M | Net income 2023 | -2.39B -15.26M | EV / Sales 2022 | 171 x |
Net cash position 2022 | 2.93B 18.72M | Net cash position 2023 | 1.47B 9.39M | EV / Sales 2023 | - |
P/E ratio 2022 |
-3.61
x | P/E ratio 2023 |
-1.61
x | Employees | 37 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 83.39% |
1 week | -1.28% | ||
Current month | -19.79% | ||
1 month | -17.20% | ||
3 months | -32.46% | ||
6 months | -42.96% | ||
Current year | -37.90% |
Managers | Title | Age | Since |
---|---|---|---|
Haru Morita
FOU | Founder | 54 | 15-12-31 |
Naoki Kobayashi
DFI | Director of Finance/CFO | 60 | - |
Tetsuya Yamagata
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Joseph McCracken
BRD | Director/Board Member | 70 | 18-07-31 |
Toshio Furuta
BRD | Director/Board Member | 62 | 18-11-30 |
Haru Morita
FOU | Founder | 54 | 15-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 77 | 0.00% | 147,800 |
24-04-25 | 77 | 0.00% | 89,000 |
24-04-24 | 77 | 0.00% | 164,600 |
24-04-23 | 77 | -2.53% | 499,500 |
24-04-22 | 79 | +1.28% | 191,100 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-37.90% | 16.73M | |
-2.44% | 103B | |
+1.93% | 95.28B | |
+1.69% | 22.15B | |
-15.42% | 21.02B | |
-8.58% | 18.15B | |
-41.01% | 16.73B | |
-13.12% | 16.05B | |
+4.14% | 13.68B | |
+35.44% | 12.17B |
- Stock Market
- Equities
- 4883 Stock